Varespladib and Cardiovascular Events in Patients With an Acute Coronary Syndrome: The VISTA-16 Randomized Clinical Trial

Study Questions:

What are the effects of secretory phospholipase A2 (sPLA2) inhibition with varespladib on cardiovascular outcomes?